Recursion Pharmaceuticals Archives - Medical Design Sourcing

In sync with the JP Morgan Health Care Conference, Recursion Pharmaceuticals has unveiled Phenom-Beta, a deep learning model designed to transform cell microscopy images into meaningful biological representations. “Phenom-Beta allows you to take images of human cells from a microscope or other sources and turn them into mathematical representations of biology,” said Chris Gibson, CEO of Recursion, in an NVIDIA-hosted call with journalists.

Hosted on the NVIDIA BioNeMo platform, Phenom-Beta is the company’s first in a potential series of foundation models for external use. The name “Phenom-Beta” references both “phenomenal” and “phenomics.” The scientist Steven A. Garan coined “phenomics” in 1996 to refer to the study of phenotypes, the observable characteristics or traits of an organism influenced by genetic predisposition and environmental factors.

Recursion bets the new frontier in phenomics could echo the rise of genomics

[NicoElNino/Adobe Stock]

The pharma industry is embracing artificial intelligence (AI) to streamline drug discovery and development, although adoption remains early. The field, however, is rapidly expanding. The global AI in drug discovery market was worth about $1.1 billion last year but could grow at a 30% clip from 2023 to 2030, according to Grand View Research.

In the years to come, AI could find use to discover an array of drug targets while improving drug developers’ ability to design molecules based on fine-grained criteria. Here, we spotlight several companies exploring the use of AI in drug discovery and drug development.

1. Exscientia

Oxford, UK–based Exscientia (Nasdaq: EXAI) has pioneered AI in small-molecule drug design. The company has expanded its AI-based platform to develop novel therapeutic antibodies through generative AI design. In early 2020, the company reported the first AI-d…

Recursion Pharmaceuticals

Recursion partners with NVIDIA to unveil Phenom-Beta, democratizing access to its $1 Billion phenomics investment

10 pioneering companies implementing AI in drug discovery, development and beyond